Wai Chun Bio-Technology (HKG:0660) widened its attributable loss for the year ended June 30 to HK$44.2 million from HK$15.4 million in the year-ago period, a Dec. 20 filing on the Hong Kong bourse stated.
Loss per share was HK$0.258, up from HK$0.091 in the corresponding period of the last fiscal year.
The modified starch and other biochemical product company's revenue fell by 52% to HK$370.1 million in the fiscal year from HK$773.7 million a year prior.
The firm attributed the higher loss mainly to the recognition of impairment losses on non-financial assets in the fiscal year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.